HONG KONG – After a successful phase II study, Beyondspring Inc.'s plinabulin is set to enter the phase III global trial known as Study 105 to test the drug's efficacy in preventing chemotherapy-induced neutropenia (CIN) associated with docetaxel.
HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) announced plans to welcome pre-revenue biopharmaceutical startups, interest in going public here has spiked among early stage firms across Greater China. Listing in Hong Kong would open an avenue to new funds raised through this major stock market.
HONG KONG – South Korea is looking to artificial intelligence (AI) to spearhead drug development in hopes of catching up with its Western peers and securing a stronger foothold in the global market.
HONG KONG – After a successful phase II study, Beyondspring Inc.'s plinabulin is set to enter the phase III global trial known as Study 105 to test the drug's efficacy in preventing chemotherapy-induced neutropenia (CIN) associated with docetaxel.
HONG KONG – Ever since the Hong Kong Stock Exchange (HKEX) announced plans to welcome pre-revenue biopharmaceutical startups, interest in going public here has spiked among early stage firms across Greater China. Listing in Hong Kong would open an avenue to new funds raised through this major stock market.
HONG KONG – South Korea is looking to artificial intelligence (AI) to spearhead drug development in hopes of catching up with its Western peers and securing a stronger foothold in the global market.
HONG KONG – Hong Kong Polytechnic University (PolyU) is partnering with two European institutions to establish a life sciences and engineering R&D platform to spearhead applied research.
